Loading...
OTCM
STME
Market cap95mUSD
Dec 03, Last price  
0.32USD
1D
-9.83%
1Q
18.56%
Jan 2017
18.56%
IPO
166.75%
Name

Cell MedX Corp

Chart & Performance

D1W1MN
OTCM:STME chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
-17.99%
Rev. gr., 5y
25.74%
Revenues
0k
000042,62436,5576,2200095,8246,7626,0652,76200
Net income
-566k
L+297.44%
0-15,859-12,636-18,527-1,032,165-2,139,137-1,249,446-1,546,798-922,702-1,113,767-1,139,085-723,065-495,042-142,486-566,293
CFO
-142k
L-2.95%
0-19,249-12,636-9,778-316,811-421,572-754,059-449,427-307,542-925,844-560,432-450,591-272,209-145,898-141,600

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.
IPO date
Mar 11, 2013
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT